Ann: Imugene B Cell & OV Platforms Featured at ESMO Congress, page-122

The statement you provided describes the results of a vaccination approach in patients with HER-2-overexpressing gastric cancer (GC).

Let's break down what this means:HER-Vaxx-based vaccination: This refers to a vaccination strategy that is designed to target HER-2/neu, a protein that is overexpressed in some cancer cells, including gastric cancer.

The vaccination likely involves administering a vaccine (HER-Vaxx) to the patients.HER-2-overexpressing GC: This specifies the type of cancer being targeted. It's gastric cancer (GC) in which the HER-2/neu protein is overexpressed. Overexpression of HER-2/neu is associated with more aggressive cancer and is a therapeutic target.Induced anti-HER-2-IgG and IgG1 subclass antibody responses (p<0.001):

This indicates that the vaccination led to the production of antibodies against the HER-2 protein. IgG antibodies are a class of antibodies in the immune system, and IgG1 is a subclass of IgG. The "p<0.001" suggests that the production of these antibodies was statistically significant, indicating a strong immune response.Dose-dependent functionality in binding to Her-2/neu-expressing cells:

This means that the antibodies produced by the vaccination have the ability to bind effectively to cancer cells that overexpress the HER-2/neu protein. Moreover, the effectiveness of this binding increases with the vaccine dose, showing a dose-dependent response.Intracellular phosphorylation inhibition of the receptor and the signaling pathway kinases Akt and MAPK:

This indicates that the antibodies generated by the vaccination are not only binding to the HER-2/neu protein on the surface of cancer cells but are also capable of inhibiting the phosphorylation of the receptor and the downstream signaling pathway kinases Akt and MAPK.

This is a critical result because it suggests that the vaccination is interfering with the cancer cell's growth and signaling processes.

In summary, the HER-Vaxx-based vaccination in patients with HER-2-overexpressing gastric cancer appears to be effective. It induces a strong immune response, resulting in the production of antibodies that can bind to cancer cells and, importantly, inhibit the intracellular signaling pathways related to cell growth. This is a promising development in the treatment of HER-2/neu-positive gastric cancer